---
title: "Taltz (ixekizumab) in plaque psoriasis: Guidelines questions"
description: "Guidelines questions on Taltz (ixekizumab) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Taltz pediatric safety: what do AAD-NPF guidelines say about IBD in children? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/guidelines"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Taltz (ixekizumab) in plaque psoriasis: Guidelines questions

Manufacturer: Eli Lilly and Company  
Prescribing information: [Taltz](https://uspl.lilly.com/taltz/taltz.html#pi)

Questions that apply to every indication of Taltz are on [Taltz (ixekizumab), all indications](https://www.evicenter.com/medical-information/taltz).

## Guidelines

<a id="taltz-pediatric-ibd-guidelines"></a>

### Taltz pediatric safety: what do AAD-NPF guidelines say about IBD in children?

Applies to: Moderate-to-severe plaque psoriasis in pediatric patients 6 to less than 18 years of age

> “The joint American Academy of Dermatology–National Psoriasis Foundation pediatric guidelines cite that the prevalence rate of IBD in children with psoriasis is thought to be 3 to 4 times higher than in children without psoriasis. Additionally, the guidelines suggest that pediatric patients with psoriasis have a higher prevalence rate of Crohn’s disease versus ulcerative colitis.<sup>12</sup>”

Source: [TALTZ: Pediatric Psoriasis Treatment Efficacy & Safety, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/pediatric-psoriasis#:~:text=The%20joint%20American%20Academy%20of,of%20Crohn%E2%80%99s%20disease%20versus%20ulcerative)

> “Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82:161-201.”

Source: [TALTZ: Pediatric Psoriasis Treatment Efficacy & Safety, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/pediatric-psoriasis#:~:text=Menter%20A%2C%20Cordoro%20KM%2C%20Davis,J%20Am%20Acad%20Dermatol.%202020%3B82%3A161%2D201.)

Note: The guideline statement describes children with psoriasis in general. The second passage is the reference the Taltz HCP pediatric psoriasis page cites for it.

## Related pages
- [Medical information: Taltz (ixekizumab): Plaque psoriasis](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/dosing-and-administration)
